NICE u-turn backs Takeda’s Adcetris for sALCL
admin 29th August 2017 Uncategorised 0Takeda’s Adcetris has now been backed by the National Institute for Health and Care Excellence as an option to treat systemic anaplastic large cell lymphoma (sALCL), a very rare and aggressive cancer of the lymphatic system, on the NHS in England and Wales.
More: NICE u-turn backs Takeda’s Adcetris for sALCL
Source: News